iotaSciences

iotaSciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

iotaSciences is a private, tools-and-services company operating in the high-growth cell therapy and regenerative medicine sector. Its core value proposition is providing automated, gentle, and efficient solutions for single-cell manipulation, a critical bottleneck in advanced cell biology research and therapeutic development. By miniaturizing processes to nanoliter volumes, the company aims to reduce costs, improve monoclonality assurance, and accelerate the creation of precisely engineered cell lines for its clients in academia and industry. The business model combines the sale/use of proprietary instrumentation with fee-for-service laboratory work, positioning it as an enabler for next-generation therapies.

Cell TherapyRegenerative Medicine

Technology Platform

Automated single-cell isolation and cloning systems using proprietary low-volume GRID culture chambers for nanoliter-scale cell dispensing and culture. Focus on gentle handling and high viability for sensitive cells like iPSCs.

Opportunities

The company is positioned at the convergence of several high-growth trends: the stringent regulatory need for proven monoclonality in cell therapy, the expanding use of fragile iPSCs in research, and the broader single-cell analysis revolution.
Its miniaturized technology also offers a compelling cost-saving value proposition in reagent-heavy workflows.

Risk Factors

Key risks include competition from established and emerging single-cell tool companies, the challenge of displacing entrenched manual methods like limiting dilution, and the scalability and quality-control demands of its services business.
As a private company, access to growth capital is also a perennial concern.

Competitive Landscape

iotaSciences competes in the single-cell isolation and cloning market against companies like Berkeley Lights (now part of Bruker), Cytena (part of BICO), Millenyi Biotec (CliniMACS), and other providers of fluorescence-activated cell sorting (FACS) and microfluidic platforms. Its differentiation lies in its specific focus on gentleness and viability for challenging cells like iPSCs, its nanoliter-volume GRID technology, and its integrated service offering for gene-editing.